SR One Capital Management LP Acquires 1,111,111 Shares of Mineralys Therapeutics, Inc. $MLYS

Key Points

• SR One Capital Management LP increased its stake in Mineralys Therapeutics by 55.1% in Q1, now holding 3,127,933 shares valued at approximately $49.67 million.
• Several institutional investors, including Vanguard and Jennison Associates, have significantly increased their investments in Mineralys, reflecting strong market interest in the company.
• The stock has a recent target price range from various analysts, with HC Wainwright setting a target of $42.00 and Wall Street Zen rating it a sell.

SR One Capital Management LP lifted its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 55.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 3,127,933 shares of the company's stock after acquiring an additional 1,111,111 shares during the quarter. Mineralys Therapeutics accounts for 12.8% of SR One Capital Management LP's investment portfolio, making the stock its 3rd largest position. SR One Capital Management LP owned 4.82% of Mineralys Therapeutics worth $49,672,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Dimensional Fund Advisors LP acquired a new position in shares of Mineralys Therapeutics in the 4th quarter worth approximately $202,000. GAMMA Investing LLC lifted its holdings in shares of Mineralys Therapeutics by 9,602.2% in the 1st quarter. GAMMA Investing LLC now owns 8,829 shares of the company's stock worth $140,000 after acquiring an additional 8,738 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Mineralys Therapeutics in the 4th quarter worth approximately $48,000. Bank of America Corp DE increased its stake in Mineralys Therapeutics by 12.0% during the 4th quarter. Bank of America Corp DE now owns 107,703 shares of the company's stock worth $1,326,000 after buying an additional 11,549 shares during the period. Finally, ProShare Advisors LLC purchased a new stake in Mineralys Therapeutics during the 4th quarter worth approximately $128,000. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Mineralys Therapeutics Stock Down 5.7%

NASDAQ MLYS traded down $0.87 on Tuesday, hitting $14.47. 1,302,442 shares of the stock were exchanged, compared to its average volume of 816,805. Mineralys Therapeutics, Inc. has a fifty-two week low of $8.24 and a fifty-two week high of $18.38. The company has a market cap of $959.22 million, a PE ratio of -4.06 and a beta of -0.29. The company has a 50-day moving average price of $14.00 and a 200-day moving average price of $13.61.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.12. As a group, equities research analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Insider Transactions at Mineralys Therapeutics

In other news, CFO Adam Scott Levy sold 59,925 shares of the business's stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $14.76, for a total transaction of $884,493.00. Following the completion of the sale, the chief financial officer owned 132,934 shares in the company, valued at approximately $1,962,105.84. The trade was a 31.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Malcom Rodman sold 11,365 shares of the business's stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $12.93, for a total transaction of $146,949.45. Following the sale, the insider owned 92,891 shares of the company's stock, valued at $1,201,080.63. This represents a 10.90% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 123,051 shares of company stock worth $1,776,262. 33.24% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

MLYS has been the topic of several recent research reports. Wall Street Zen downgraded shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. Guggenheim set a $48.00 target price on shares of Mineralys Therapeutics and gave the stock a "buy" rating in a research note on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and set a $42.00 target price on shares of Mineralys Therapeutics in a research note on Wednesday, August 13th. Finally, Jefferies Financial Group initiated coverage on shares of Mineralys Therapeutics in a research note on Tuesday, June 10th. They set a "hold" rating and a $15.00 target price on the stock. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $32.25.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.